Anticoagulation in Blunt Cerebrovascular Injuries

Overview

Originally thought to be a rare occurrence, BCVI are now diagnosed in approximately 1% of blunt trauma patients. Initially BCVI were thought to have unavoidable devastating neurologic outcomes. But early reports suggested anticoagulation might decrease these events. If untreated, carotid artery injuries (CAI) have a stoke rate up to 50% depending on injury grade, with increasing stroke rates correlating with increasing grades of injury. Current studies report early treatment with antithrombotics – either heparin or anti-platelet agents – in patients with BCVI markedly reduces stroke rates and resultant neurologic morbidity. As reports of bleeding complications have altered heparin protocols in these patients, the use of antiplatelet agents is attractive. Although heparin has been has been proposed as the gold standard treatment due to its initial empiric use, no comparative studies of antithrombotic agents has been performed. In sum, Grade I-III blunt carotid and vertebral arterial injuries (BCVI) have the potential for stroke, and should be treated. Heparin has not been shown to clearly improve healing rates compared with antiplatelet therapy. The purpose of this study is to determine whether systemic anticoagulation alters the course of Grade I-III BCVI compared with antiplatelet therapy. The investigators study hypothesis is that Grade I-III BCVI will heal or progress to pseudoaneurysm formation, independent of systemic antithrombotic regimen, and that the combination of aspirin and clopidogrel is equally efficacious in preventing neurologic symptoms compared to systemic heparin associated with Grade I-III BCVI.

Full Title of Study: “Anticoagulation in the Management of Grade I-III Blunt Cerebrovascular Injuries”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2008

Interventions

  • Drug: heparin
  • Drug: aspirin and clopidogrel

Clinical Trial Outcome Measures

Primary Measures

  • Neurologic sequelae
    • Time Frame: during hospital visit

Participating in This Clinical Trial

Inclusion Criteria

  • Patients greater than 18 years old with documented grade I-III blunt cerebrovascular injuries. Exclusion Criteria:

  • Pregnancy – Nasal polyps – Previous gastrointestinal bleeding secondary to antiplatelet medications – Contraindication to systemic anticoagulation.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • C. Clay Cothren, MD
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: C. Clay Cothren, MD, Principal Investigator – Denver Health and Hospital Authority
  • Overall Official(s)
    • Clay Cothren, MD, Principal Investigator, Denver Health Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.